(Q34344990)

1 August 2017

1 reference

title

Insulin resistance and beta-cell dysfunction as therapeutic targets in type 2 diabetes (English)

1 reference

1 August 2017

1 reference

1 reference

Evans AJ

1

1 reference

1 August 2017

Krentz AJ

series ordinal

2

1 reference

1 August 2017

publication date

1 August 2001

1 reference

Diabetes, Obesity and Metabolism

1 August 2017

published in

1 reference

1 August 2017

volume

3

1 reference

1 August 2017

issue

4

1 reference

1 August 2017

page(s)

219-229

1 reference

Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. WHO Ad Hoc Diabetes Reporting Group

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Pathogenesis of non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Insulin resistance or insulin deficiency. Which is the primary cause of NIDDM?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Banting lecture 1988. Role of insulin resistance in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Insulin resistance: a multifaceted metabolic syndrome. Insights gained using a low-dose insulin infusion technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Role of insulin resistance in the pathogenesis of NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Prospective study of cigarette smoking, alcohol use, and the risk of diabetes in men

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Drug Treatment of Hypertension in Patients With Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

The metabolically obese, normal-weight individual revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

New diagnostic criteria for diabetes--are they doing what they should?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Glucose transporters and insulin action--implications for insulin resistance and diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulin-dependent) diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Role of fatty acids in the pathogenesis of insulin resistance and NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Cardiovascular actions of insulin in humans. Implications for insulin sensitivity and vascular tone

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Hypothesis: muscle insulin resistance is the ("not-so") thrifty genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Fetal origins of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

The fetal insulin hypothesis: an alternative explanation of the association of low birthweight with diabetes and vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Measurement of insulin secretion in type 2 diabetes: problems and pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Effect of sulphonylurea therapy on plasma insulin, intact and 32/33 split proinsulin in subjects with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Islet amyloid polypeptide: does it play a pathophysiological role in the development of diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Insulin resistance is central to the burden of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Insulin resistance and insulin deficiency in the pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: errors of metabolism or of methods?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Comparative tolerability profiles of oral antidiabetic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

UKPDS and beyond: into the next millennium. United Kingdom Prospective Diabetes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Recent developments and emerging therapies for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Thiazolidinediones: a new class of antidiabetic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

PPARgamma, the ultimate thrifty gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

The polycystic ovary syndrome: treatment with insulin sensitizing agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Benefits and risks of transfer from oral agents to insulin in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Insulin analogues and their potential in the management of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

21 January 2018

A drug on the market?

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Metabolic consequences of weight loss on glucose metabolism and insulin action in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Sibutramine. A review of its contribution to the management of obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Relation between leptin and the regulation of glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Science, medicine, and the future. Obesity treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Preventing non-insulin-dependent diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Diabetes: a time for excitement-and concern. Hopeful signs exist that the ravages of diabetes can be tamed

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

Insulin action and non-esterified fatty acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00101.X

10.1046/J.1463-1326.2001.00101.X

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference